Evogene (EVGN) EBITDA Margin Growth (3y) (2015 - 2026)
Evogene (EVGN) EBITDA Margin Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -537.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1,934.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7,261.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,003.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -11,254.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30,461.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -2,649.00 |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 11,710.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,710.00 |
| Dec 31, 2025 | -108,684.00 |
| Sep 30, 2025 | 64,988.00 |
| Jun 30, 2025 | 221,895.00 |
| Mar 31, 2025 | 326,954.00 |
| Dec 31, 2024 | 256,932.00 |
| Sep 30, 2024 | 532,600.00 |
| Jun 30, 2024 | 475,043.00 |
| Mar 31, 2024 | 178,206.00 |
| Dec 31, 2023 | 72,501.00 |
| Sep 30, 2023 | 164,624.00 |
| Jun 30, 2023 | 54,559.00 |
| Mar 31, 2023 | 808,378.00 |
| Dec 31, 2022 | 535,887.00 |
| Sep 30, 2022 | 354,199.00 |
| Jun 30, 2022 | -11,687.00 |
| Mar 31, 2022 | -205,707.00 |
| Dec 31, 2021 | -196,541.00 |
| Sep 30, 2021 | -427,576.00 |
| Jun 30, 2021 | -428,257.00 |